This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
CRESEMBA® is suitable for the renally impaired – even those with ESRD1
CRESEMBA® has no cyclodextrin in its IV formulation, which means that it has reduced potential for renal toxicity compared with other azoles.1,5–7
It can be used in patients with renal dysfunction, including ESRD, without dose adjustments.1
Treatment outcomes with CRESEMBA® appear to be unaffected by kidney function.8,9 There is no evidence of loss of efficacy or drug safety concerns in patients with renal impairment, and median hospital LOS may be reduced vs voriconazole in patients with moderate-to-severe impairment (p=0.0032).8,9
With liposomal amphotericin B, nephrotoxicity can be a concern, and renal adverse events are a common reason for treatment discontinuation.10
Could using CRESEMBA® in patients with renal impairment help you stay focused on their underlying condition?
CRESEMBA® may simplify treatment in patients with hepatic impairment1
CRESEMBA® has significantly improved hepatic tolerability vs voriconazole: the frequency of drug-related hepatobiliary AEs in the SECURE trial was 9% and 16%, respectively (p=0.016).2
Unlike voriconazole, CRESEMBA® does not require dose adjustments in patients with mild or moderate hepatic dysfunction (Child-Pugh A and B).1,5
Although elevated liver transaminases have been reported, they rarely require treatment discontinuation.1
CRESEMBA® has not been studied in severe hepatic impairment; use in these patients is not recommended unless the potential benefit outweighs the risks.1
With liposomal amphotericin B, hepatotoxicity remains a concern, with hepatic adverse events being a common reason for treatment discontinuation.10
Could using CRESEMBA® in patients with hepatic impairment help you stay focused on their underlying condition?
CRESEMBA® does not cause QTc prolongation1
While voriconazole and posaconazole prolong the QTc interval, CRESEMBA® doesn’t.1,5,6,11 This may be a valuable consideration in patients with proarrhythmic risk.
CRESEMBA® shortens the QTc interval; it is therefore contraindicated in patients with familial short QT syndrome, and should be used with caution in combination with medicines that cause QTc shortening.1
In patients with proarrhythmic risk, could CRESEMBA® be a consideration?
CRESEMBA® has fewer and more manageable drug–drug interactions than other azoles1,3
Compared with other azoles, CRESEMBA® can help simplify the management of patients taking certain concomitant medications.1,3,5,6
As the table below shows, CRESEMBA® has fewer CYP450 effects vs other azoles.1,3
Adapted from reference 12.
This means CRESEMBA® can be administered with several medications without the need to dose-adjust.1
Adapted from: reference 12.
This means CRESEMBA® can be administered with several medications without the need to dose-adjust.1
Adapted from reference 1.
CRESEMBA® can be used with ibrutinib
The BTK inhibitor ibrutinib is increasingly being prescribed for the treatment of B-cell malignancies such as CLL, MCL and WM.13–15 Ibrutinib therapy has been associated with an increased incidence of invasive fungal infections, particularly invasive aspergillosis.14–16
Unlike voriconazole, posaconazole and itraconazole, CRESEMBA® can be used with ibrutinib, and coadministration appears to be well tolerated.13,16
a. CRESEMBA® is contraindicated in coadministration with ketoconazole, high-dose ritonavir, and strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates, phenytoin and St. John’s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine.1 For further details and a full list of drug interactions, please refer to Local Product Document.
AE, adverse event; BTK, Bruton’s tyrosine kinase; CLL, chronic lymphocytic leukaemia; CYP, cytochrome P; ESRD, end-stage renal disease; IV, intravenous; LOS, length of stay; MCL, mantle cell lymphoma; PK, pharmacokinetics; TDM, therapeutic drug monitoring; WM, Waldenström’s macroglobulinaemia.
Prescribing Information:
References:
PP-CRB-IND-0472 July 2022
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Optional footnote area for disclaimers etc.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.